دورية أكاديمية
Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg).
| العنوان: | Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg). |
|---|---|
| المؤلفون: | Martínez-Domínguez SJ; Department of Gastroenterology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.; Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Facultad de Medicina, Universidad de Zaragoza, Zaragoza, Spain.; Centro de Investigación Biomédica en Red en Enfermedades Digestivas y Hepáticas (CIBERehd), Madrid, Spain., Nyssen OP; Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, Universidad Autónoma de Madrid (UAM), Madrid, Spain., Lanas Á; Department of Gastroenterology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.; Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Facultad de Medicina, Universidad de Zaragoza, Zaragoza, Spain.; Centro de Investigación Biomédica en Red en Enfermedades Digestivas y Hepáticas (CIBERehd), Madrid, Spain., Alfaro E; Department of Gastroenterology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.; Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Facultad de Medicina, Universidad de Zaragoza, Zaragoza, Spain.; Centro de Investigación Biomédica en Red en Enfermedades Digestivas y Hepáticas (CIBERehd), Madrid, Spain., Jonaitis L; Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania., Mahmudov U; Modern Hospital, Baku, Azerbaijan., Voynovan I; Department of Gastroenterology, A.S. Loginov Moscow Clinical Scientific Center, Moscow, Russia., Gülüstan B; Azerbaijan State Advanced Training Institute for Doctors Named by A.Aliyev, Baku, Azerbaijan., Rodrigo L; Department of Gastroenterology, University of Oviedo, Oviedo, Spain., Fiorini G; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Perez-Aisa Á; Department of Gastroenterology, Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS), Hospital Universitario Costa del Sol, Marbella, Spain., Tejedor-Tejada J; Department of Gastroenterology, Hospital Universitario de Cabueñes, Gijón, Asturias, Spain., Tepes B; Department of Gastroenterology, DC Rogaska, Rogaska Slatina, Slovenia., Vologzanina L; Gastrocenter, Perm, Russia., Mammadov E; Azerbaijan State Advanced Training Institute for Doctors Named by A.Aliyev, Baku, Azerbaijan., Lerang F; Østfold Hospital Trust, Grålum, Norway., Oğlu QFV; National Oncology Centre, Baku, Azerbaijan., Bakulina NV; I.I. Mechnikov North-Western State Medical University of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia., Abdulkhakov R; Department of Hospital Medicine, Kazan State Medical University, Kazan, Russia., Tatiana I; Department of Gastroenterology, SM-Clinic, Saint-Petersburg, Russia., Butler TJ; Department of Gastroenterology, Clinical Medicine, Trinity College Dublin, Tallaght University Hospital, Dublin, Ireland., Sarsenbaeva AS; Department of Gastroenterology, Chelyabinsk Regional Clinical Hospital, Chelyabinsk, Russia., Bumane R; Digestive Diseases Centre GASTRO, Riga, Latvia., Lucendo AJ; Department of Gastroenterology, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Hospital General de Tomelloso, Tomelloso, Spain., Romano M; Gastroenterology and Endoscopy Unit, Dipartimento di Medicina di Precisione, Università Vanvitelli, Naples, Italy., Bujanda L; Centro de Investigación Biomédica en Red en Enfermedades Digestivas y Hepáticas (CIBERehd), Madrid, Spain.; Department of Gastroenterology, Biodonostia Health Research Institute, San Sebastián, Spain.; Department of Medicine, Universidad del País Vasco (UPV/EHU), San Sebastián, Spain., Abdulkhakov SR; I.I. Mechnikov North-Western State Medical University of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia., Zaytsev O; First Clinical Medical Centre, Kovrov, Russia., Pabón-Carrasco M; Department of Gastroenterology, Hospital Universitario de Valme, Sevilla, Spain., Keco-Huerga A; Department of Gastroenterology, Hospital Universitario de Valme, Sevilla, Spain., Denkovski M; Interni Oddelek, Diagnostic Centre, Bled, Slovenia., Huguet JM; Department of Gastroenterology, Hospital General Universitario de Valencia, Valencia, Spain., Perona M; Department of Gastroenterology, Hospital Quirón Marbella, Marbella, Spain., Núñez Ó; Department of Gastroenterology, Hospital Universitario Sanitas La Moraleja, Madrid, Spain., Pavoni M; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Fadieienko G; Department the Division for the Study of the Digestive Diseases and its Comorbidity with Noncommunicable Diseases, Government Institution L.T. Malaya Therapy National Institute of NAMS of Ukraine, Kharkiv, Ukraine., Alekseenko S; Far Eastern State Medical University, Khabarovsk, Russia., Smith SM; School of Medicine, Trinity College Dublin, Dublin, Ireland., Hernández L; Gastroenterology Unit, Hospital Santos Reyes, Aranda de Duero, Spain., Kupcinskas J; Department of Gastroenterology, Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania., Bordin DS; Department of Pancreatic, Biliary and Upper Digestive Tract Disorders, A. S. Loginov Moscow Clinical Scientific Center, Moscow, Russia.; Department of Outpatient Therapy and Family Medicine, Tver State Medical University, Tver, Russia.; Department of Propaedeutic of Internal Diseases and Gastroenterology, Russian University of Medicine, Moscow, Russia., Leja M; Department of Gastroenterology, Digestive Diseases Centre, Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia., Gasbarrini A; Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Gridnyev O; Department the Division for the Study of the Digestive Diseases and its Comorbidity with Noncommunicable Diseases, Government Institution L.T. Malaya Therapy National Institute of NAMS of Ukraine, Kharkiv, Ukraine., Cano-Català A; Gastrointestinal Oncology, Endoscopy and Surgery (GOES) Research Group, Institut de Recerca i Innovació en Ciències de la Vida i de la Salut de la Catalunya Central (IRIS-CC), Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Spain., Parra P; Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, Universidad Autónoma de Madrid (UAM), Madrid, Spain., Moreira L; Department of Gastroenterology, Centro de Investigación Biomédica en red en Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain., Mégraud F; INSERM U1312 Bric, Université de Bordeaux, Bordeaux, France., O'Morain C; Faculty of Health Sciences, Trinity College Dublin, Dublin, Ireland., Gisbert JP; Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, Universidad Autónoma de Madrid (UAM), Madrid, Spain. |
| مؤلفون مشاركون: | Hp‐EuReg Investigators |
| المصدر: | Helicobacter [Helicobacter] 2024 Jul-Aug; Vol. 29 (4), pp. e13111. |
| نوع المنشور: | Clinical Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9605411 Publication Model: Print Cited Medium: Internet ISSN: 1523-5378 (Electronic) Linking ISSN: 10834389 NLM ISO Abbreviation: Helicobacter Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford : Wiley-Blackwell Original Publication: Malden, MA : Wiley-Blackwell, c1996- |
| مواضيع طبية MeSH: | Anti-Bacterial Agents*/therapeutic use , Helicobacter Infections*/drug therapy , Helicobacter pylori*/drug effects, Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Young Adult ; Drug Therapy, Combination ; Europe ; Prospective Studies ; Treatment Outcome |
| مستخلص: | Background: The influence of indications for Helicobacter pylori investigation on prescriptions and effectiveness is unknown. The aim of the study was to assess the impact of indications for H. pylori investigation on prescriptions, effectiveness, compliance, and tolerance. Methods: International, prospective, non-interventional registry of the management of H. pylori infection by European gastroenterologists (Hp-EuReg). Treatment-näive patients registered from 2013 to 2023 at e-CRF AEG-REDCap were analyzed. The effectiveness was assessed by modified intention-to-treat analysis. Results: Overall, 53,636 treatment-naïve cases from 34 countries were included. Most frequent indications were: dyspepsia with normal endoscopy (49%), non-investigated dyspepsia (20%), duodenal ulcer (11%), gastric ulcer (7.7%), and gastroesophageal reflux disease (GERD) (2.6%). Therapy effectiveness varied by indication: duodenal ulcer (91%), gastric ulcer (90%), preneoplastic lesions (90%), dyspepsia with normal endoscopy (89%), GERD (88%), and non-investigated dyspepsia (87%). Bismuth-metronidazole-tetracycline and clarithromycin-amoxicillin-bismuth quadruple therapies achieved 90% effectiveness in all indications except GERD. Concomitant clarithromycin-amoxicillin-tinidazole/metronidazole reached 90% cure rates except in patients with non-investigated dyspepsia; whereas sequential clarithromycin-amoxicillin-tinidazole/metronidazole proved optimal (≥90%) in patients with gastric ulcer only. Adverse events were higher in patients treated for dyspepsia with normal endoscopy and duodenal ulcer compared with the remaining indications (23% and 28%, p < 0.001). Therapeutic compliance was higher in patients with duodenal ulcer and preneoplastic lesions (98% and 99%, p < 0.001). Conclusion: In Europe, patients with gastric or duodenal ulcers and preneoplastic lesions showed higher H. pylori treatment effectiveness. Bismuth and non-bismuth quadruple therapies achieved optimal results in almost all indications. Trial Registration: ClinicalTrials.gov identifier: NCT02328131. (© 2024 The Author(s). Helicobacter published by John Wiley & Sons Ltd.) |
| التعليقات: | Erratum in: Helicobacter. 2024 Jul-Aug;29(4):e13124. doi: 10.1111/hel.13124. (PMID: 39108214) |
| References: | P. Malfertheiner, M. C. Camargo, E. El‐Omar, et al., “Helicobacter pylori Infection,” Nature Reviews Disease Primers 9, no. 1 (2023): 19. A. Lanas and F. K. L. Chan, “Peptic Ulcer Disease,” Lancet 390, no. 10094 (2017): 613–624. Z. Wang, X. Gao, R. Zeng, et al., “Changes of the Gastric Mucosal Microbiome Associated With Histological Stages of Gastric Carcinogenesis,” Frontiers in Microbiology 11 (2020): 997. J. P. Gisbert, X. Calvet, F. Bermejo, et al., “III Spanish Consensus Conference on Helicobacter pylori Infection,” Gastroenterología y Hepatología 36, no. 5 (2013): 340–374. P. Malfertheiner, F. Megraud, T. Rokkas, et al., “Management of Helicobacter pylori Infection: The Maastricht VI/Florence Consensus Report,” Gut 71, no. 9 (2022): 1724–1762. O. P. Nyssen, D. Bordin, B. Tepes, et al., “European Registry on Helicobacter pylori Management (Hp‐EuReg): Patterns and Trends in First‐Line Empirical Eradication Prescription and Outcomes of 5 Years and 21533 Patients,” Gut 70, no. 1 (2021): 40–54. I. Ariño‐Pérez, S. J. Martínez‐Domínguez, E. Alfaro Almajano, P. Carrera‐Lasfuentes, and Á. Lanas, “Mistakes in the Diagnosis and Treatment of Helicobacter pylori Infection in Daily Clinical Practice,” Helicobacter 28, no. 4 (2023): e12957. I. Ariño Pérez, S. J. Martínez‐Domínguez, E. Alfaro Almajano, P. Carrera‐Lasfuentes, and Á. Lanas, “Management of Helicobacter pylori Infection and Effectiveness Rates in Daily Clinical Practice in Spain: 2010–2019,” Antibiotics 11, no. 5 (2022): 698. V. Laredo, C. Sostres, E. Alfaro, M. T. Arroyo, and Á. Lanas, “Management of Helicobacter pylori Infection at the Primary Care Level. The Implementation of Specific Counseling Improves Eradication Rates,” Helicobacter 24, no. 3 (2019): e12586. A. G. McNicholl, D. S. Bordin, A. Lucendo, et al., “Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More Than 90% of Patients,” Clinical Gastroenterology and Hepatology 18, no. 1 (2020): 89–98. L. Bujanda, O. P. Nyssen, D. Vaira, et al., “Antibiotic Resistance Prevalence and Trends in Patients Infected With Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp‐EuReg),” Antibiotics 10, no. 9 (2021): 1058. O. P. Nyssen, A. Perez‐Aisa, B. Tepes, et al., “Adverse Event Profile During the Treatment of Helicobacter pylori: A Real‐World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp‐EuReg),” American Journal of Gastroenterology 116, no. 6 (2021): 1220–1229. A. G. McNicholl, C. A. O'Morain, F. Megraud, et al., “Protocol of the European Registry on the Management of Helicobacter pylori Infection (Hp‐EuReg),” Helicobacter 24, no. 5 (2019): e12630. P. A. Harris, R. Taylor, R. Thielke, J. Payne, N. Gonzalez, and J. G. Conde, “Research Electronic Data Capture (REDCap)—A Metadata‐Driven Methodology and Workflow Process for Providing Translational Research Informatics Support,” Journal of Biomedical Informatics 42, no. 2 (2009): 377–381. D. Y. Graham, H. Lu, and M. P. Dore, “Relative Potency of Proton‐Pump Inhibitors, Helicobacter pylori Therapy Cure Rates, and Meaning of Double‐Dose PPI,” Helicobacter 24, no. 1 (2019): e12554. J. Kirchheiner, S. Glatt, U. Fuhr, et al., “Relative Potency of Proton‐Pump Inhibitors‐Comparison of Effects on Intragastric pH,” European Journal of Clinical Pharmacology 65, no. 1 (2009): 19–31. E. Tshibangu‐Kabamba and Y. Yamaoka, “Helicobacter pylori Infection and Antibiotic Resistance—From Biology to Clinical Implications,” Nature Reviews. Gastroenterology & Hepatology 18, no. 9 (2021): 613–629. European Centre for Disease Prevention and Control, World Health Organization, Antimicrobial resistance surveillance in Europe 2022 – 2020 data, Publication Office of the European Union, 2022, https://data.europa.eu/doi/10.2900/112339. W. D. Chey, G. I. Leontiadis, C. W. Howden, and S. F. Moss, “ACG Clinical Guideline: Treatment of Helicobacter pylori Infection,” American Journal of Gastroenterology 112, no. 2 (2017): 212–239. A. Savoldi, E. Carrara, D. Y. Graham, M. Conti, and E. Tacconelli, “Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta‐Analysis in World Health Organization Regions,” Gastroenterology 155, no. 5 (2018): 1372–1382.e17. F. Mégraud, D. Y. Graham, C. W. Howden, et al., “Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe,” American Journal of Gastroenterology 118, no. 2 (2023): 269–275. M. Caldas, Á. Pérez‐Aisa, M. Castro‐Fernández, et al., “European Registry on Helicobacter pylori Management: Effectiveness of First and Second‐Line Treatment in Spain,” Antibiotics 10, no. 1 (2020): 13. P. Jonaitis, O. P. Nyssen, I. M. Saracino, et al., “Comparison of the Management of Helicobacter pylori Infection Between the Older and Younger European Populations,” Scientific Reports 13, no. 1 (2023): 17235. L. Fernández‐Salazar, A. Campillo, L. Rodrigo, et al., “Effectiveness and Safety of High‐Dose Dual Therapy: Results of the European Registry on the Management of Helicobacter pylori Infection (Hp‐EuReg),” Journal of Clinical Medicine 11, no. 12 (2022): 3544. O. P. Nyssen, D. Vaira, Á. Pérez Aísa, et al., “Empirical Second‐Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp‐EuReg),” Clinical Gastroenterology and Hepatology 20, no. 10 (2022): 2243–2257. S. J. Hong and S. W. Kim, “Helicobacter pylori Infection in Gastroesophageal Reflux Disease in the Asian Countries,” Gastroenterology Research and Practice 2015 (2015): 1–6. P. Gatenby and Y. Soon, “Barrett's Oesophagus: Evidence From the Current Meta‐Analyses,” World Journal of Gastrointestinal Pathophysiology 5, no. 3 (2014): 178–187. W. Schwizer, D. Menne, K. Schütze, et al., “The Effect of Helicobacter pylori Infection and Eradication in Patients With Gastro‐Oesophageal Reflux Disease: A Parallel‐Group, Double‐Blind, Placebo‐Controlled Multicentre Study,” United European Gastroenterology Journal 1, no. 4 (2013): 226–235. N. Vakil, N. J. Talley, M. Stolte, et al., “Patterns of Gastritis and the Effect of Eradicating Helicobacter pylori on Gastro‐Oesophageal Reflux Disease in Western Patients With non‐ulcer Dyspepsia,” Alimentary Pharmacology & Therapeutics 24, no. 1 (2006): 55–63. Y. W. Chang, W. J. Ko, C. H. Oh, et al., “Clarithromycin Resistance and Female Gender Affect Helicobacter pylori Eradication Failure in Chronic Gastritis,” Korean Journal of Internal Medicine 34, no. 5 (2019): 1022–1029. E. Peña‐Galo, J. Gotor, Y. Harb, M. Alonso, and J. Alcedo, “Socioeconomic and Demographic Factors Associated With Failure in Helicobacter pylori Eradication Using the Standard Triple Therapy,” Gastroenterology and Hepatology From Bed to Bench 14, no. 1 (2021): 53–58. W. A. De Boer and G. N. J. Tytgat, “Review: The Best Therapy for Helicobacter pylori Infection: Should Efficacy or Side‐Effect Profile Determine Our Choice?” Scandinavian Journal of Gastroenterology 30, no. 5 (1995): 401–407. J. Molina‐Infante, A. J. Lucendo, T. Angueira, et al., “Optimised Empiric Triple and Concomitant Therapy for Helicobacter pylori Eradication in Clinical Practice: The OPTRICON Study,” Alimentary Pharmacology & Therapeutics 41, no. 6 (2015): 581–589. V. F. Gil‐Guillen, A. Balsa, B. Bernárdez, et al., “Medication Non‐Adherence in Rheumatology, Oncology and Cardiology: A Review of the Literature of Risk Factors and Potential Interventions,” International Journal of Environmental Research and Public Health 19, no. 19 (2022): 12036. P. Kardas, P. Lewek, and M. Matyjaszczyk, “Determinants of Patient Adherence: A Review of Systematic Reviews,” Frontiers in Pharmacology 4 (2013): 91. |
| معلومات مُعتمدة: | European Helicobacter and Microbiota Study Group (EHMSG); Spanish Association of Gastroenterology (AEG); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd); 101095359 European Union Programme HORIZON; 10058099 UK Research and Innovation; 101101252 European Union Programme EU4Health; Diasorin; Translational Research in Digestive Diseases of Aragón Health Research Institute and the CIBERehd |
| فهرسة مساهمة: | Keywords: Helicobacter pylori; compliance; effectiveness; indications; safety |
| سلسلة جزيئية: | ClinicalTrials.gov NCT02328131 |
| المشرفين على المادة: | 0 (Anti-Bacterial Agents) |
| تواريخ الأحداث: | Date Created: 20240713 Date Completed: 20240713 Latest Revision: 20240807 |
| رمز التحديث: | 20240807 |
| DOI: | 10.1111/hel.13111 |
| PMID: | 39001621 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1523-5378 |
|---|---|
| DOI: | 10.1111/hel.13111 |